Free Trial

Ginkgo Bioworks (DNA) Short Interest Ratio & Short Volume

Ginkgo Bioworks logo
$12.72 +1.14 (+9.84%)
As of 02:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ginkgo Bioworks Short Interest Data

Ginkgo Bioworks (DNA) has a short interest of 7.37 million shares, representing 20.20% of the float (the number of shares available for trading by the public). This marks a 2.79% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.9, indicating that it would take 5.9 days of the average trading volume of 1.36 million shares to cover all short positions.

Current Short Interest
7,370,000 shares
Previous Short Interest
7,170,000 shares
Change Vs. Previous Month
+2.79%
Dollar Volume Sold Short
$72.37 million
Short Interest Ratio
5.9 Days to Cover
Last Record Date
December 31, 2024
Outstanding Shares
57,480,000 shares
Float Size
36,490,000 shares
Short Percent of Float
20.20%
Today's Trading Volume
1,202,780 shares
Average Trading Volume
1,360,987 shares
Today's Volume Vs. Average
88%
Short Selling Ginkgo Bioworks?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Ginkgo Bioworks and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

DNA Short Interest Over Time

DNA Days to Cover Over Time

DNA Percentage of Float Shorted Over Time

Ginkgo Bioworks Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
12/31/20247,370,000 shares $72.37 million +2.8%20.2%5.9 $9.82
12/15/20247,170,000 shares $67.68 million -3.4%19.7%6.1 $9.44
11/30/20247,420,000 shares $64.55 million +1.4%20.4%5.7 $8.70
11/15/20247,320,000 shares $46.63 million -0.1%19.7%5.5 $6.37
10/31/20247,330,000 shares $55.93 million -7.0%20.7%5.4 $7.63
10/15/20247,880,000 shares $61.46 million -3.8%22.2%5.5 $7.80
9/30/20248,190,000 shares $66.87 million +29.0%23.1%5.5 $8.17
9/15/20246,350,000 shares $40.13 million -11.2%17.9%3.6 $6.32
8/31/20247,150,000 shares $47.83 million +86.2%20.2%4.5 $6.69
8/15/20243,840,000 shares $974,976.00 -96.9%10.8%2.6 $0.25
7/31/2024123,460,000 shares $46.91 million +27.0%8.7%2.1 $0.38
7/15/202497,240,000 shares $28.19 million -19.7%6.9%1.6 $0.29
6/30/2024121,100,000 shares $40.48 million -49.2%8.5%2.1 $0.33
6/15/2024238,220,000 shares $107.13 million -2.9%17.0%5.1 $0.45
5/31/2024245,410,000 shares $128.57 million -10.6%17.7%6.1 $0.52
5/15/2024274,440,000 shares $232.09 million -5.3%19.7%7.2 $0.85
4/30/2024289,730,000 shares $258.18 million +8.7%20.8%9.4 $0.89
4/15/2024266,530,000 shares $253.76 million -1.6%19.7%10.8 $0.95
3/31/2024270,830,000 shares $314.16 million +3.3%20.2%12.2 $1.16
3/15/2024262,240,000 shares $283.22 million +2.6%19.6%11.9 $1.08
2/29/2024255,720,000 shares $391.25 million +2.2%19.1%11.2 $1.53
2/15/2024250,230,000 shares $387.86 million +5.6%19.0%11.8 $1.55
1/31/2024236,910,000 shares $286.66 million +1.3%18.0%11.2 $1.21
1/15/2024233,850,000 shares $304.01 million -0.7%17.7%11.1 $1.30
12/31/2023235,500,000 shares $398.00 million -1.5%17.8%12.1 $1.69
12/15/2023239,070,000 shares $382.51 million +3.7%18.1%12.1 $1.60
11/30/2023230,480,000 shares $297.32 million +3.4%17.5%12.4 $1.29
11/15/2023222,910,000 shares $345.51 million -5.5%17.2%11.4 $1.55
10/31/2023235,940,000 shares $323.24 million +2.2%18.6%11.9 $1.37
10/15/2023230,820,000 shares $383.16 million -1.2%18.2%11.6 $1.66
9/30/2023233,540,000 shares $422.71 million -0.4%18.4%10.7 $1.81
9/15/2023234,530,000 shares $452.64 million +13.2%18.5%10.8 $1.93
8/31/2023207,170,000 shares $484.78 million +0.4%16.4%9 $2.34
8/15/2023206,330,000 shares $367.27 million -3.9%16.4%8.5 $1.78
7/31/2023214,590,000 shares $538.62 million -1.4%17.2%9.1 $2.51
7/15/2023217,710,000 shares $444.13 million -2.4%17.4%9.4 $2.04
6/30/2023223,020,000 shares $414.82 million +20.6%17.8%10.3 $1.86
6/15/2023184,920,000 shares $361.52 million +0.9%14.8%8.7 $1.96
5/31/2023183,290,000 shares $289.60 million -9.4%14.7%9.1 $1.58
5/15/2023202,240,000 shares $266.96 million +7.5%16.2%10.1 $1.32
Did You See Trump’s Manhattan Project Bombshell? (Ad)

This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.

4/30/2023188,130,000 shares $229.52 million -4.4%15.3%10 $1.22
4/15/2023196,750,000 shares $255.78 million +2.1%16.7%10.2 $1.30
3/31/2023192,710,000 shares $256.30 million +11.3%19.1%9.7 $1.33
3/15/2023173,100,000 shares $230.22 million +18.4%17.1%8.3 $1.33
2/28/2023146,150,000 shares $214.84 million +16.8%14.5%6.8 $1.47
2/15/2023125,180,000 shares $227.83 million +1.4%12.4%5.9 $1.82
1/31/2023123,490,000 shares $240.81 million -1.6%12.1%5.3 $1.95
1/15/2023125,510,000 shares $233.45 million -0.6%12.4%5.3 $1.86
12/30/2022126,250,000 shares $213.36 million +10.5%12.5%5.2 $1.69
12/15/2022114,290,000 shares $186.29 million -3.6%11.0%4.5 $1.63
11/30/2022118,570,000 shares $235.95 million -4.7%12.6%4.8 $1.99
11/15/2022124,380,000 shares $332.09 million -7.3%13.2%5 $2.67
10/31/2022134,220,000 shares $366.42 million -14.1%15.7%4.9 $2.73
10/15/2022156,300,000 shares $404.82 million -8.8%19.2%5.9 $2.59
9/30/2022171,280,000 shares $534.39 million -8.7%24.2%6.8 $3.12
9/15/2022187,610,000 shares $587.22 million +4.8%22.1%7.4 $3.13
8/31/2022179,060,000 shares $481.67 million +24.1%22.8%7 $2.69
8/15/2022144,250,000 shares $503.43 million -4.0%18.4%5.5 $3.49
7/31/2022150,270,000 shares $429.77 million +3.9%19.8%6.5 $2.86
7/15/2022144,640,000 shares $433.92 million +7.5%19.1%6.2 $3.00
6/30/2022134,540,000 shares $320.21 million +22.4%17.8%5.7 $2.38
6/15/2022109,920,000 shares $284.69 million -14.7%14.6%4.3 $2.59
5/31/2022128,780,000 shares $396.64 million +19.1%17.1%5.6 $3.08
5/15/2022108,160,000 shares $287.71 million +16.9%14.4%5.2 $2.66
4/30/202292,500,000 shares $268.25 million +13.8%11.8%5 $2.90
4/15/202281,300,000 shares $312.19 million +9.7%10.3%4.6 $3.84
3/31/202274,120,000 shares $298.70 million -16.4%9.4%4.4 $4.03
3/15/202288,670,000 shares $258.03 million +2.9%9.3%7.1 $2.91
2/28/202286,190,000 shares $387.86 million +1.5%9.4%7.3 $4.50
2/15/202284,950,000 shares $471.47 million -9.2%9.2%7.5 $5.55
1/31/202293,570,000 shares $559.55 million +30.3%10.2%8.9 $5.98
1/15/202271,830,000 shares $415.90 million +30.0%8.6%8.2 $5.79
12/31/202155,270,000 shares $459.29 million No Change6.4%7 $8.31

DNA Short Interest - Frequently Asked Questions

What is Ginkgo Bioworks' current short interest?

Short interest is the volume of Ginkgo Bioworks shares that have been sold short but have not yet been closed out or covered. As of December 31st, investors have sold 7,370,000 shares of DNA short. 20.20% of Ginkgo Bioworks' shares are currently sold short. Learn More on Ginkgo Bioworks' current short interest.

What is a good short interest ratio for Ginkgo Bioworks?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNA shares currently have a short interest ratio of 6.0. Learn More on Ginkgo Bioworks's short interest ratio.

Which institutional investors are shorting Ginkgo Bioworks?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ginkgo Bioworks: Jane Street Group LLC, Wolverine Trading LLC, Walleye Trading LLC, and Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Ginkgo Bioworks?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 20.20% of Ginkgo Bioworks' floating shares are currently sold short.

Is Ginkgo Bioworks' short interest increasing or decreasing?

Ginkgo Bioworks saw a increase in short interest in December. As of December 31st, there was short interest totaling 7,370,000 shares, an increase of 2.8% from the previous total of 7,170,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Ginkgo Bioworks' float size?

Ginkgo Bioworks currently has issued a total of 57,480,000 shares. Some of Ginkgo Bioworks' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ginkgo Bioworks currently has a public float of 36,490,000 shares.

How does Ginkgo Bioworks' short interest compare to its competitors?

20.20% of Ginkgo Bioworks' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ginkgo Bioworks: Edgewise Therapeutics, Inc. (9.84%), HUTCHMED (China) Limited (0.27%), Arrowhead Pharmaceuticals, Inc. (8.04%), Mirum Pharmaceuticals, Inc. (13.39%), Harmony Biosciences Holdings, Inc. (14.10%), CG Oncology, Inc. (16.39%), Protagonist Therapeutics, Inc. (6.38%), NewAmsterdam Pharma (5.51%), Janux Therapeutics, Inc. (16.41%), Vera Therapeutics, Inc. (14.59%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks.

What does it mean to sell short Ginkgo Bioworks stock?

Short selling DNA is an investing strategy that aims to generate trading profit from Ginkgo Bioworks as its price is falling. DNA shares are trading up $0.72 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Ginkgo Bioworks?

A short squeeze for Ginkgo Bioworks occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DNA, which in turn drives the price of the stock up even further.

How often is Ginkgo Bioworks' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNA, twice per month. The most recent reporting period available is December, 31 2024.




This page (NYSE:DNA) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners